1. Карпов Ю.А., Шальнова С.А., Деев А.Д. Престариум у больных артериальной гипертонией и ишемической болезнью сердца (или факторами риска) — безопасное достижение целевого уровня артериального давления (ПРЕМЬЕРА): результаты клинического этапа национальной программы // Кардиология. — 2006. — № 6. — С. 21–27. / Karpov Yu.A., Shalnova S.A., Deev A.D. Prestarium in hypertension and coronary artery disease (or in patients with risk factors) — safe achievement of target BP (PREMIER): results of the clinical stage of national program // Cardiology. — 2006. — Vol. 6. — Р. 21–27.
2. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр) // Системные гипертензии. — 2010. — № 3. — С. 5–26. / Russian medical hypertension society, Russian scientiic cardiology society. Diagnosis and treatment of hypertension. Russian guidelines (4 edition) // System Hypertensions. — 2010. — Vol. 3. — Р. 5–26.
3. Перепеч Н.Б. Лечение больных с сочетанием артериальной гипертензии и ишемической болезни сердца — новые возможности // Consilium Medicum. — 2011. — Т. 13, № 5. — С. 20–25. / Perepech N.B. Treatment of patients with combination of hypertension and coronary artery disease — new opportunities // Consilium Medicum. — 2011. — Vol. 13, № 5. — Р. 20–25.
4. ADVANCE Collaborative Group. Effects of ixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial // Lancet. — 2007. — Vol. 370, № 9590. — Р. 828–840.
5. Dahlof B., Sever P.S., Poulter N.R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrolumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial // Lancet. — 2005. —Vol. 366, № 9489. — Р. 895-906.
6. Cleland J.G.F., Tendera M., Adamus J. et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) // Eur. Heart J. — 2006. — Vol. 27, № 19. — Р. 2338–2345.
7. Neaton J.D., Wentworth D. for the multiple risk factor intervention Trial Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall indings and differences by age for 316,099 white men // Arch. Intern. Med. — 1992. — Vol. 152, № 1. — Р. 56–64.
8. Ferrari R. for the PREAMI investigators. Effects of ACE inhibition with perindopril on left ventricular remodeling and clinical outcome // Arch. Intern. Med. — 2006. — Vol. 166, № 6. — Р. 659–666.
9. Jamerson K.A., Weber M.A., Bakris G.L. et al. on behalf of the ACCOMPLISH investigators. Benazepril plus amlodipine or hydrochlorotiazide for hypertension in high-risk patients // N. Engl. J. Med. — 2008. — Vol. 359, № 23. — Р. 2417–2428.
10. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan- or amlodipine-based regimens: VALUE, a randomised trial // Lancet. — 2004. — Vol. 363, № 9426. — Р. 2022–2031.
11. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M. et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronaryartery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial // J. Am. Med. Assoc. —2003. — Vol. 290, № 21. — Р. 2805–2816.
12. Perindopril: a major contribution to the prevention and treatment of cardiovascular disease / Ed. by F. Ferrari, K.M. Fox. — Volters Kluwer, 2008. — 13 р.
13. SYMBIO: Results of a longitudinal study of optimized blood pressurelowering therapy with ixed combination perindopril/amlodipine. ESH2010.
14. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody. 2007 Guidelines for the management of arterial hypertension // J. Hypertens. — 2007. — Vol. 25, № 6. — Р. 1105–1187.
15. The ALLHAT Oficers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic (ALLHAT) // J. Am. Med. Assoc. — 2002. — Vol. 288, № 23. — Р. 2981–2997.
16. The EUROPA investigators. Eficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) // Lancet. — 2003. — Vol. 362, № 9386. — Р. 782–788.
17. The PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering among 6105 individuals with previous stroke or transient ischaemic attack // Lancet. — 2001. — Vol. 358, № 9287. — Р. 1033–1041.
